This final pitch night is the culmination of our 10-week Biomedical Business Plan Challenge. After a competitive application process, seven Weill Cornell Medicine faculty led teams were selected to work with 15+ mentors throughout the Spring to refine business plans and pitches for their new biomedical ventures.
Each team will pitch its' business to a panel of esteemed investors for a chance to win numerous cash and sponsor prizes.
The award ceremony will be followed by a reception with light appetizers and refreshments and will provide invaluable networking with members of the academic, industry, investment, and entrepreneurial communities.
Raghav Bhargava
Associate, New Enterprise Associates
Raghav Bhargava joined NEA as an associate on the healthcare team in 2018. Prior to joining NEA, Raghav was a member of Lazard’s healthcare M&A group in New York. At Lazard, Raghav worked with clients across the life sciences, medical device, and healthcare services sectors. Raghav graduated from the Roy and Diana Vagelos Program at the University of Pennsylvania, where he earned a B.A. in Biology from the College of Arts and Sciences and a B.S. in Economics from the Wharton School. During his time at the University of Pennsylvania, Raghav conducted both laboratory research and advisory work related to engineered T cell therapy for oncology.
Oren Eisner
Founder and CEO, Soundview Capital Partners LP
Oren Eisner is the founder and CEO of Soundview Capital Partners LP, an investment firm focused on biotech companies developing assets that serve real-world unmet medical needs. Soundview seeks to accelerate the development of these assets by investing directly in companies and providing long term financing. Soundview partners with the companies in which it invests and collaborates with them throughout all stages of development. Before forming Soundview, Oren spent over 11 years at QVT Financial LP. BA from Yale University; JD from Cornell University, Magna Cum Laude
Jenna Foger, MS
Senior Vice President, Science & Technology, Alexandria Real Estate Equities, Inc./Alexandria Venture Investments
Jenna Foger is a Senior Vice President on Alexandria’s Science & Technology team, which provides scientific expertise and strategic industry insights to support the company’s real estate operations, venture investments, thought leadership, and business development initiatives. In her role, she leads venture investment activities and other ecosystem initiatives for Alexandria’s New York City life science cluster, most recently spearheading the strategic planning of Alexandria LaunchLabs, NYC’s premier startup life science platform, as well as the Alexandria Seed Capital Platform. Prior to joining Alexandria, Jenna worked as an Associate at Windham Venture Partners, a boutique healthcare venture capital firm focused on growth-stage medical device, diagnostic, and digital health investments, where she assisted in growing the fund’s life science investment practice. Before Windham, she was a Senior Consultant at Navigant Consulting (formerly Easton Associates), a leading NYC-based healthcare consulting firm specializing in new product evaluation and strategic planning for companies across the life science industry. Jenna also obtained extensive laboratory experience as a Neurobiology Research Associate at The Rockefeller University. She earned her master’s in Biotechnology from Columbia University and graduated Phi Beta Kappa summa cum laude from the University of Pennsylvania with a BA in Cognitive Neuroscience and Psychology
Samuel Bjork
Principal, Digitalis Ventures
Samuel received graduate degrees from Cambridge and Oxford University as a Marshall Scholar and an A.B. in Chemistry from Harvard University. Prior to Digitalis, Samuel was a member of the healthcare and clean energy practices at the Boston Consulting Group.
Jonathan Gordon, MBA
Director, New York Presbyterian Ventures
Jonathan Gordon is Director of NYP Ventures, the strategic venture capital arm of New York-Presbyterian, where he is responsible for managing the hospital’s venture investment fund, building strategic partnerships and managing the hospital’s IP portfolio. Previously, Jon was a Director in the Hospital’s Office of Strategy, where he worked on projects ranging from launching the hospital’s Medicare accountable care organization to building a telehealth program. Jon is also Director of the Health Policy Center at New York-Presbyterian, which advocates for the role of Academic Health Centers in developing solutions for the American healthcare system. Jon serves on faculty at Weill Cornell Medicine, and teaches about healthcare transformation. Prior to joining NYP, Jon helped found and served as Chief Operating Officer of EveryDay Medical, an e-commerce-based provider of durable medical equipment. Jon is a Mentor for the German Accelerator and Blueprint Health incubator, a board member for NYCEDC’s Digital Health Breakthrough Network and a Director of Costs of Care, a not-for-profit dedicated to increasing cost awareness among clinicians. Jon holds a BA cum laude from Princeton University and an MBA with honors from Columbia Business School.
Arthur Klausner, MBA
President & CEO, Goldilocks Therapeutics, Inc.
Arthur Klausner is currently CEO of Goldilocks Therapeutics, Inc., a start-up company formed to advance nanoparticle technology developed at Memorial Sloan Kettering Cancer Center for the treatment of acute kidney injury. He had previously served as CEO and a Boardmember of Gem Pharmaceuticals (acquired by Monopar Therapeutics in 2017), and CEO and a Boardmember of Jade Therapeutics (acquired by EyeGate Pharmaceuticals in 2016). Prior to his operating roles, Arthur spent a total of 18 years as a life sciences venture capitalist at Domain Associates and Pappas Ventures. During that time, he was involved in the investment in and subsequent nurturing of a variety of biotechnology, specialty pharmaceutical, and medical device companies.. Arthur began his venture capital career after earning an M.B.A. at the Stanford University Graduate School of Business. Previously, Arthur had spent six years at Bio/Technology magazine (now Nature Biotechnology), where as Senior Editor he researched and prepared over 200 articles concerning scientific and business aspects of applied biology. He has also performed consulting projects for the U.S. Office of Technology Assessment, Arthur D. Little Decision Resources, and a range of pharmaceutical and biotechnology companies. His undergraduate degree in Biology is from Princeton University.
Whitney Snider, MD, MBA
Principal, Inning One Ventures
Whitney Snider is a Principal at Inning One Ventures, an early stage life science venture capital fund, dedicated to creating the next generation of breakthrough biotechnology companies. Whitney was formerly a Director of Business Development at Celgene Corporation where she led and facilitated acquisitions, equity investments, collaborations and diligence teams for a range of strategic oncology, inflammation and immunology and neurodegeneration target opportunities. Deals of note include Vividion ($101M research collaboration and equity investment), Delinia ($300M acquisition), Evotec ($45M research collaboration and equity investment), Anokion ($45M research collaboration and equity investment) and Grail ($50M equity investment). Whitney was formerly a Consultant at Bain & Company where she led primary research, financial analysis and evaluations of organizational structures for private equity clients and Fortune 1000 healthcare companies. Whitney received her ScB from Brown University, MD from Tufts University School of Medicine, and MBA from Harvard Business School.
5:30PM Registration
6:00PM Welcome
Larry Schlossman, Managing Director, Business Development, BioPharma Alliances and Research Collaborations, Weill Cornell Medicine
Jahan Ali, PhD, Director, BioVenture eLab, Weill Cornell Medicine
6:15PM Pitches Start
7:30PM Awards Ceremony and Reception
Hors d'oeuvres and refreshments will be served.